Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Nicolas Penel; Antoîne Italiano; Jennifer Wallet; L. Chaigneau; B. Verret; Nelly Firmin; Sarah Watson; Thibaud Valentin; Emmanuelle Bompas; François Bertucci; Mehdi Brahmi; Clémence Hénon; Angélique Brunot; Mariella Spalato Ceruso; Marie Vanseymortier; E Heyman-Decoupigny; Thomas Ryckewaert; Marie‐Cécile Le Deley; Christophe Perrin; Jean Yves Blay

doi:10.1016/j.annonc.2025.03.024

Shared by

Jean Yves Blay

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Article 2025 en

Authors

NP
Nicolas Penel
AI
Antoîne Italiano
JW
Jennifer Wallet

Abstract

1 min read

This trial met its primary objective, regorafenib significantly delayed disease progression after first-line treatment in advanced non-adipocytic STS. This was associated with a non-significant trend of overall survival improvement.

Discussion(0)

No comments yet. Be the first to comment.

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Abstract

Discussion(0)

Related publications

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Supplementary Material for: Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts.

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

Related publications

Article2004
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
Article2004

Dataset
Supplementary Material for: Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Article2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Article2016

Article2022
Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts.
Article2022

Editorial Material2016
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
Editorial Material2016